Introduction
============

Langerhans cell histiocytosis (LCH) is a rare disorder affecting adults and children, characterised by an abnormal accumulation of epidermal Langerhans-like cells in various sites ([@b1-ol-0-0-6774]--[@b3-ol-0-0-6774]). The aetiology and pathogenesis of LCH remains to be established, but it is hypothesized to be a clonal disorder ([@b4-ol-0-0-6774],[@b5-ol-0-0-6774]). A diagnosis of LCH is made following the detection of lesional cluster of differentiation (CD)1a^+^ Langerhans-like cells, whereas non-Langerhans histiocytoses, including Erdheim Chester disease, are CD1a^−^. LCH is a heterogeneous disease, affecting all ages and ethnicities, and disease may take a variety of courses: Certain disease cases may spontaneously remit, while other cases may lead to fatality. Risk factors include the time to diagnosis and the site of lesions ([@b6-ol-0-0-6774]).

A study from the Histiocyte Society recognised a disparity in the site, age of onset and incidence of LCH between adults and children ([@b7-ol-0-0-6774]). The age of onset in children is between 1--3 years, whereas adult disease is more heterogeneous, with a higher incidence in young (18--30 years) and older adults (\>70 years) ([@b7-ol-0-0-6774]). The reported incidence of LCH ranges from 0.5--5.4 cases per million persons per year ([@b8-ol-0-0-6774]--[@b10-ol-0-0-6774]), but these figures are largely associated with childhood disease. The incidence of adult disease is likely to be underreported, as LCH is frequently treated according to the affected system, without a secondary referral. Childhood disease is more likely to be referred to an oncologist, providing more accurate statistics.

Although childhood LCH lesions tend to predominate in bone ([@b11-ol-0-0-6774]), adult LCH is more widespread, commonly presenting in the skin, bone and lung. [Table I](#tI-ol-0-0-6774){ref-type="table"} lists the common sites of LCH in both adults and children reported in several previous studies ([@b6-ol-0-0-6774],[@b7-ol-0-0-6774],[@b12-ol-0-0-6774]). This heterogeneity, coupled with relative scarcity, renders it challenging to implement randomized control trials in adults or children to optimize therapy. Notwithstanding the Histiocyte Society\'s LCH protocol that provides a therapeutic framework, treatment for LCH is variable across centres ([@b13-ol-0-0-6774]).

Despite an unknown aetiology, the misguided myeloid dendritic cell precursor model provides one underlying mechanism to explain the abnormal localization and accumulation of dendritic cells ([@b14-ol-0-0-6774],[@b15-ol-0-0-6774]), and this is consistent with the treatment of LCH as a haematological disease (at least in paediatric cases). Haematopoietic forms of cancer occur as a consequence of arrest at a discrete stage of an ordered developmental pathway, frequently associated with distinct patterns of mutation. This is in contrast to primary and metastatic solid tumours, which tend to exhibit a higher level of heterogeneity at the genetic level ([@b16-ol-0-0-6774]). The most significant recent advance in the understanding of LCH has been provided by studies describing the high incidence of BRAF^V600E^ mutations in childhood disease ([@b17-ol-0-0-6774]--[@b19-ol-0-0-6774]). This observation, along with the immature phenotype of LCH cells, is consistent with the discrete patterns of mutation and arrested development observed in haematopoietic types of cancer. In order to further investigate whether this mutation demonstrated a discrete pattern in LCH, the current study aimed to investigate the BRAF^V600E^ status in a broader range of LCH cases (with respect to age and site) in order to establish whether there is commonality in the aetiology of a disease with heterologous presentation. In addition, the assessment of numerous biopsies from patients with LCH presenting at multiple sites may provide further evidence for a clonal origin of this disorder.

Materials and methods
=====================

### Meta-analysis

PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>) was searched for manuscripts referencing LCH biopsies that had been subject to BRAF^V600E^ screening by direct sequencing, reverse transcription-polymerase chain reaction (PCR) or immunohistochemistry. Relevant patient information (disease classification and BRAF status) from 10 published manuscripts were isolated for meta-analysis ([Table II](#tII-ol-0-0-6774){ref-type="table"}) ([@b15-ol-0-0-6774],[@b17-ol-0-0-6774]--[@b25-ol-0-0-6774]). The search criteria used were 'BRAFV600E' and 'Langerhans cell histiocytosis'. Results were filtered for adults (\>18 years) and paediatric disease (\<18 years), and secondly according to disease site, including bone or skin.

### BRAF^V600E^ sequencing

Research Ethics Committee (REC) approval at Hammersmith Hospital (London, UK) was obtained for the present study (REC reference no. 60/Q0406/107). In total, 33 adult LCH samples, representing 30 patients were available to screen for the BRAF^V600E^ mutation. DNA was extracted from 21 archival paraffin embedded LCH biopsies and 12 fresh biopsies enriched for CD1a positive cells using an AllPrep DNA/RNA FFPE kit and AllPrep DNA/RNA Mini kit from Qiagen, Inc. (Valencia, CA, USA), respectively. The extractions were performed according to the manufacturer\'s protocol. CD1a-positive cell selection was performed using MACS CD1a MicroBeads kit purchased from Miltenyi Biotec, Inc. (Cambridge, MA, USA). Cells were selcted using magnetic beads coated with a human anti-mouse IgG monoclonal antibody and a magnetic particle concentrator according to the manufacturer\'s instructions. DNA quality was assessed using a NanoDrop (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Amplification and sequencing of exon 15 of the BRAF gene was performed by Source BioScience (Nottingham, UK). Source BioScience designed the primer pairs and performed region-specific PCR optimization, amplification and sequencing. The oligonucleotide sequences were as follows: PCR forward primer (5′AAC ACA TTT CAA GCC CCA AA); PCR reverse primer (5′AGC ATC TCA GGG CCA AAA AT); forward sequencing primer (5′TCA TAA TGC TTG CTC TGA TAG GA); reverse sequencing primer (5′GGC CAA AAA TTT AAT CAG TGG A). PCR reaction mixes contained 25 ng DNA (or a no template control), 0.6 µM of each primer and Roche High-Fidelity master mix at a 1X final concentration with the following conditions: Initial denaturation at 94°C for 279 sec; followed by 35 cycles of 94°C for 20 sec, 55°C for 15 sec and 65°C for 30 sec; followed by a final elongation step at 65°C for 60 sec. PCR products were cleaned up using Zymo ZR-96 clean and concentrator kit (Zymo Research Corp, Irvine, CA, USA). Products were sequenced as standard using an ABI 3730 machine (Thermo Fisher Scientific, Inc.).

### Statistical analysis

Statistical analysis was performed using Prism statistics software (version 4; GraphPad Software, Inc., La Jolla, CA, USA). Analysis was performed using χ^2^ and Fisher\'s exact tests. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

A meta-analysis of existing LCH BRAF^V600E^ studies was performed to invesitigate the heterogeneity of LCH at the genetic level. [Fig. 1A](#f1-ol-0-0-6774){ref-type="fig"} reveals no difference in the prevalence of BRAF^V600E^ mutations between adult and paediatric LCH. Similarly, when the incidence of the BRAF^V600E^ mutation in various clinical classifications of LCH was evaluated, no significant differences were identified between multi-system (MS)-LCH and focal or single system (SS) LCH ([Fig. 1B](#f1-ol-0-0-6774){ref-type="fig"}). In addition, investigation of the mutation in varying sites revealed no consistent pattern ([Fig. 1C](#f1-ol-0-0-6774){ref-type="fig"}).

The results of BRAF^V600E^ sequencing in adult LCH cases are presented in [Table III](#tIII-ol-0-0-6774){ref-type="table"}. Of the 29 patients analysed, 11 patients exhibited a BRAF^V600E^ mutation, which corresponds to 38% of patients with LCH being BRAFV600E-positive for the mutation. There were 3 patients for whom multiple samples were analysed. Lesional gum and bone samples from patient 16 exhibited differential status with respect to the BRAF^V600E^ mutation. However, follow up with PCR revealed the two samples to be BRAF^V600E^-positive (data not shown), suggesting a low level of mutated cells in the gum sample below the sensitivity threshold of sequencing. It is of note that PCR analysis did not identify V600E mutations in any other biopsies identified as wild-type by sequencing. A total of 3 lung samples were available for patient 28, all of which were BRAF^V600E^-positive. There were two lymph node samples available for patient 20, of which one was BRAF^V600E^-positive. It is possible that one of these lymph node samples was obtained from a node not involved in the lesion; however, the clinical history of these samples is not available.

Discussion
==========

The BRAF^V600E^ mutant was present in the adult population in the current study at a slightly lower frequency than that indicated by the meta-analysis (38 vs. 47%, respectively), albeit with no discernible pattern linking the mutation to lesional site (skin or bone) or disease severity (SS or MS-LCH). While the meta-analysis revealed a higher prevalence of mutations in high-risk organs, BRAF^V600E^ status by itself does not necessarily identify high-risk disease. The present findings are broadly comparable with those reported by Berres *et al* ([@b25-ol-0-0-6774]).

Consistency in BRAF^V600E^ mutation status in more than one lesion from the same individual (with the exception of one lymph node biopsy) is consistent with a clonal origin of the disease ([@b4-ol-0-0-6774],[@b5-ol-0-0-6774]). Moreover, the fact that dendritic cells derive from circulating myeloid precursors, and that lesional Langerhans cells have an immature phenotype, suggests that LCH can be considered to be a haematological tumour ([@b14-ol-0-0-6774],[@b19-ol-0-0-6774]).

Haematopoietic forms of cancer typically exhibit arrested cell development at a discrete stage of an ordered developmental pathway, frequently associated with distinct patterns of mutation. In addition, the increased prevalence of BRAF^V600E^ mutations in higher risk organs including the liver and spleen ([Fig. 1C](#f1-ol-0-0-6774){ref-type="fig"}) was concordant with results from Héritier *et al* ([@b26-ol-0-0-6774]) suggesting that the expression of this mutation in at-risk organs increases the aggressiveness of LCH, particularly in younger patients. Clinically, LCH is currently treated as a haematological disease in paediatric cases.

BRAF mutations in haematological malignancy are relatively rare ([@b27-ol-0-0-6774],[@b28-ol-0-0-6774]). The BRAF^V600E^ mutation has a high prevalence in in hairy cell leukaemia and has been suggested to be the disease-defining event in this disorder ([@b29-ol-0-0-6774]). It is, however, rare in other B-cell or associated lymphoproliferative disorders ([@b28-ol-0-0-6774]) and is notably absent from chronic and acute myeloid neoplasms ([@b30-ol-0-0-6774],[@b31-ol-0-0-6774]).

BRAF mutation-targeting therapy, including the BRAF inhibitors vemurafenib and dabrafenib, have demonstrated evidence of therapeutic activity in several BRAF^V600E^-mutated cancer types, including hairy cell leukaemia ([@b29-ol-0-0-6774],[@b32-ol-0-0-6774]--[@b34-ol-0-0-6774]). However, the results of the current study suggest that, prior to administering BRAF therapy, clinicians must be aware that the mutation characterizes a subset of LCH and administration of such therapies should be predicted upon genotyping. Furthermore, the resistance-profile of BRAF inhibitors in melanoma ([@b35-ol-0-0-6774]) must be considered to ensure LCH is treated and eliminated, rather than driving drug resistance and limiting future clinical options.

The present study has demonstrated that BRAF^V600E^ mutations are present within a sub-population of LCH patients. The haematological tumour profile exhibited by LCH suggests that certain treatments that are currently undertaken in paediatric LCH cases and for other haematopoietic types of cancer may aid the treatment of LCH. An investigation of the effective treatments for hairy cell leukaemia may offer more therapeutic options for this disease.

The current study was sponsored by the Cotswold Trust.
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###### 

Most common sites of Langerhans cell histiocytosis in children and adults with their frequency, where reported.

                           Frequency in adults, %   Frequency in children, %            
  ------------------------ ------------------------ -------------------------- -------- ----
  Bone                     52                       77                         70--80   
  Skin                     6                        65                         10       50
  Ear, nose and throat                                                         \>15     
  Pituitary                0.9                      44                         5--50    
  Orbits                                                                       \<20     
  Mouth                                                                        6        
  Gastrointestinal tract                                                       2--13    
  Lungs                    40                       43                         \<5      12
  Liver                                             5                          4        
  Lymph nodes                                                                  \<10     
  Thyroid                                           9                                   

Adapted from ([@b6-ol-0-0-6774],[@b7-ol-0-0-6774],[@b12-ol-0-0-6774]). SSl, single-system; MS, multi-system.

###### 

Summary of Langerhans cell histiocytosis published data used for meta-analysis.

  Authors, year                 Age, years (no. of patients)   Total no. of patients   Classification   BRAF^V600E^ screening                                 V600E no. of patients   WT no. of patients   P-value   Refs.
  ----------------------------- ------------------------------ ----------------------- ---------------- ----------------------------------------------------- ----------------------- -------------------- --------- ----------------------
  Bates *et al*, 2013           \<18 (1)                       1                       SS (0)           Pyrosequencing                                        --                      --                             ([@b20-ol-0-0-6774])
                                \>18 (N/A)                                             MS (1)                                                                 1                       --                             
  Yousem *et al*, 2013          \<18 (N/A)                     5                       SS (5)           Next generation sequencing and Sanger sequencing      2                       3                              
                                \>18 (5)                                               MS (−)                                                                 --                      --                             
  Satoh *et al*, 2012           \<18 (16)                      16                      SS (9)           Next generation pyrosequencing                        6                       3                      0.615   ([@b21-ol-0-0-6774])
                                \>18 (N/a)                                             MS (7)                                                                 3                       4                              
  Badalian-Very *et al*, 2010   \<18 (27)                      52                      SS (44)          Pyrosequencing                                        27                      17                   0.700     ([@b18-ol-0-0-6774])
                                \>18 (17)                                              MS (8)                                                                 4                       4                              
  Chilosi *et al*, 2014         \<18 (11)                      38                      SS (33)          Pyrosequencing and VE1 immunoreactivity               17                      16                   0.343     ([@b17-ol-0-0-6774])
                                \>18 (27)                                              MS (5)                                                                 1                       4                              
  Haroche *et al*, 2012         \<18 (N/A)                     29                      SS (N/A)         Pyrosequencing                                        --                      --                             ([@b22-ol-0-0-6774])
                                \>18 (N/A)                                             MS (N/A)                                                               --                      --                             
  Sahm *et al*, 2012            \<18 (49)                      89                      SS (85)          Direct sequencing and VE1 immunoreactivity            31                      54                   0.154     ([@b23-ol-0-0-6774])
                                \>18 (40)                                              MS (4)                                                                 3                       1                              
  Wei *et al*, 2013             \<18 (36)                      52                      SS (43)          Direct sequencing                                     25                      18                   0.684     \(15\)
                                \>18 (16)                                              MS (7)                                                                 3                       4                              
  Berres *et al*, 2014          \<18 (97)                      100                     SS (45)          Qiagen BRAF^V600E^ qPCR mutation assay and            27                      18                   0.532     ([@b24-ol-0-0-6774])
                                \>18 (3)                                               MS (55)          Sanger sequencing                                     37                      18                             
  Go *et al*, 2014              \<18 (19)                      27                      SS (N/A)         Direst Sanger sequencing, Peptide nucleic acid        6                       21                             ([@b19-ol-0-0-6774])
                                \>18 (8)                                               MS (N/A)         clamp qPCR (PNAcqPCR) assay and Anyplex™ qPCR assay                                                          

SS, single system; MS, multi system; N/A, information not available; qPCR, quantitative-polymerase chain reaction; PNAcqPCR, peptide nucleic acid clamp real-time polymerase chain reaction; WT, wild type.

###### 

BRAF^V600E^ mutation screening in adult LCH cases using Sanger Sequencing.

  Patient no.   Type    Tissue type   Clinical status   BRAF status
  ------------- ------- ------------- ----------------- -------------
    1           Cells   N/A           LCH               WT
    2           Cells   N/A           LCH               WT
    3           Cells   Skin          MS                WT
    4           Cells   N/A           LCH               WT
    5           Cells   N/A           LCH               WT
    6           Cells   N/A           LCH               V600E
    7           Cells   BALF          SS                WT
    8           Cells   BALF          MS                WT
    9           Cells   Skin          SS                V600E
  10            Cells   BALF          SS                WT
  11            Cells   Skin          LCH               V600E
  12            Cells   BALF          SS                WT
  13            FFPE    Skin          MS-HR             WT
  14            FFPE    Skin          MS-HR             WT
  15            FFPE    Skin          MS-HR             WT
  16a           FFPE    Gum           MS                WT
  16b           FFPE    Bone                            V600E
  17            FFPE    Skin          SS                WT
  18            FFPE    Skin          SS                WT
  19            FFPE    Skin          SS                WT
  20a           FFPE    LN            LCH               WT
  20b           FFPE    LN                              V600E
  21            FFPE    LN            LCH               V600E
  22            FFPE    N/A           LCH               WT
  23            FFPE    Liver         LCH               WT
  24            FFPE    N/A           LCH               WT
  25            FFPE    Skin          LCH               V600E
  26            FFPE    Skin          MS                V600E
  27            FFPE    Skin          SS                V600E
  28a           FFPE    Lung                            V600E
  28b           FFPE    Lung          LCH               V600E
  28c           FFPE    Lung                            V600E
  29            FFPE    Thyroid       LCH               V600E

FFPE, formalin-fixed paraffin-embedded; N/A, information not available; BALF, bronchoalveolar lavage fluid; LN, lymph node; SS, single system; MS, multisystem; MS-HR, multisystem high risk; WT, wild type; LCH, Langerhans cell histiocytosis of unknown status.
